WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Med Air Africa
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
INDUSTRIAL IMPACT
The Bracken Group | October 11, 2021
Three unique companies with shared origins have now united to better serve their clients in the life sciences industry. The new entity will be known as The Bracken Group (Bracken) with three divisions of the original three companies. The combined companies' mission continues to be supporting the success of companies that improve health, using an integrated network of clients, consultants, and employees across the globe. I am delighted to bring the ...
Labiotech.eu | January 27, 2020
The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...
Willow Biosciences Inc. | February 01, 2022
Willow Biosciences Inc. a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST. During the webcast, Willow's President and Chief Executive Officer Trevor Peters will provide a presentation through a PowerPoint discussion that will cover key areas of Willow's business. After the formal presentation, investors w...
CELL AND GENE THERAPY
Mnemo Therapeutics | January 24, 2022
The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy. The study demonstrates high antigen sensitivity of HLA-independent T-cell receptors, created by editing the TCR Alpha Constant chain locus in human peripheralbio blood Tcells. Low antigen expression<...
Article
MEDICAL
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE